» Articles » PMID: 7499226

V-src Induces Prostaglandin Synthase 2 Gene Expression by Activation of the C-Jun N-terminal Kinase and the C-Jun Transcription Factor

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1995 Nov 17
PMID 7499226
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

A consensus cyclic AMP response element (CRE) in the murine prostaglandin synthase-2 (PGS2) promoter is essential for pgs2 gene expression induced by pp60v-src, the v-src oncogene product. In this study, we investigate (i) the transcription factors active at the PGS2 "CRE site" in response to v-src activation and (ii) the signal transduction pathways by which pp60v-src activates these transcription factors. Transient transfection assays with pgs2 promoter/luciferase reporter chimeric genes suggest that c-Jun mediates v-src-induced pgs2 gene expression. Antibody supershift experiments demonstrate that c-Jun can participate in a complex with the pgs2 promoter CRE site. Moreover, in vitro immuno-complex assays demonstrate that pp60v-src expression strongly activates c-Jun N-terminal kinase (JNK1) enzyme activity. Serines 63 and 73, the sites of c-Jun phosphorylation by JNK, are essential for v-src-induced, pgs2 promoter-mediated luciferase expression. Cotransfection studies with plasmids expressing wild-type JNK, dominant-negative JNK, and dominant-negative MEKK-1 confirm that activation of the Ras/MEKK-1/JNK/c-Jun pathway is required for v-src-induced pgs2 gene expression. Overexpression of either wild-type ERK-1 or ERK-2 proteins also potentiate v-src-mediated luciferase expression driven by the pgs2 promoter, and expression of dominant-negative mutants of ERK-1, ERK-2, or Raf-1 attenuate this response. Thus, in response to v-src expression, a Ras/MEKK-1/JNK signal transduction pathway activating c-Jun and a Ras/Raf-1/ERK pathway converge to mediate pgs2 gene expression via the CRE site in the pgs2 promoter.

Citing Articles

The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.

Saliakoura M, Reynoso-Moreno I, Pozzato C, Rossi Sebastiano M, Galie M, Gertsch J Oncogene. 2020; 39(14):2948-2960.

PMID: 32034305 PMC: 7118021. DOI: 10.1038/s41388-020-1196-5.


Therapeutic Approaches of Resveratrol on Endometriosis via Anti-Inflammatory and Anti-Angiogenic Pathways.

Dull A, Moga M, Dimienescu O, Sechel G, Burtea V, Anastasiu C Molecules. 2019; 24(4).

PMID: 30781885 PMC: 6413140. DOI: 10.3390/molecules24040667.


COX-2 metabolic products, the prostaglandin I and F, mediate the effects of TNF-α and Zn in stimulating the phosphorylation of Tau.

Wang Y, Guan P, Yu X, Guo Y, Zhang Y, Wang Z Oncotarget. 2017; 8(59):99296-99311.

PMID: 29245902 PMC: 5725093. DOI: 10.18632/oncotarget.21853.


Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

Li N, Li H, Su F, Li J, Ma X, Gong P Int J Clin Exp Pathol. 2015; 8(8):9010-20.

PMID: 26464643 PMC: 4583875.


Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Li H, Wang Y, Su F, Li J, Gong P Int J Clin Exp Pathol. 2015; 8(5):5577-83.

PMID: 26191267 PMC: 4503138.